List of Excipients in API griseofulvin oral suspension
✉ Email this page to a colleague
Excipients in ANDA-approved (generic) drugs containing griseofulvin oral suspension
Detailed excipient profiles for griseofulvin oral suspension
Excipient focus: ALCOHOL
griseofulvin oral suspension drug variants containing ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| TriRx Huntsville Pharmaceutical Services LLC | griseofulvin oral suspension | 80432-056 |
| >Company | >Ingredient | >NDC |
griseofulvin oral suspension drug variants not containing ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: DIMETHICONE
griseofulvin oral suspension drug variants containing DIMETHICONE
| Company | Ingredient | NDC |
|---|---|---|
| TriRx Huntsville Pharmaceutical Services LLC | griseofulvin oral suspension | 80432-056 |
| >Company | >Ingredient | >NDC |
griseofulvin oral suspension drug variants not containing DIMETHICONE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: DOCUSATE SODIUM
griseofulvin oral suspension drug variants containing DOCUSATE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| TriRx Huntsville Pharmaceutical Services LLC | griseofulvin oral suspension | 80432-056 |
| >Company | >Ingredient | >NDC |
griseofulvin oral suspension drug variants not containing DOCUSATE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FD&C RED NO. 40
griseofulvin oral suspension drug variants containing FD&C RED NO. 40
| Company | Ingredient | NDC |
|---|---|---|
| TriRx Huntsville Pharmaceutical Services LLC | griseofulvin oral suspension | 80432-056 |
| >Company | >Ingredient | >NDC |
griseofulvin oral suspension drug variants not containing FD&C RED NO. 40
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FD&C YELLOW NO. 6
griseofulvin oral suspension drug variants containing FD&C YELLOW NO. 6
| Company | Ingredient | NDC |
|---|---|---|
| TriRx Huntsville Pharmaceutical Services LLC | griseofulvin oral suspension | 80432-056 |
| >Company | >Ingredient | >NDC |
griseofulvin oral suspension drug variants not containing FD&C YELLOW NO. 6
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM ALUMINUM SILICATE
griseofulvin oral suspension drug variants containing MAGNESIUM ALUMINUM SILICATE
| Company | Ingredient | NDC |
|---|---|---|
| TriRx Huntsville Pharmaceutical Services LLC | griseofulvin oral suspension | 80432-056 |
| >Company | >Ingredient | >NDC |
griseofulvin oral suspension drug variants not containing MAGNESIUM ALUMINUM SILICATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MENTHOL
griseofulvin oral suspension drug variants containing MENTHOL
| Company | Ingredient | NDC |
|---|---|---|
| TriRx Huntsville Pharmaceutical Services LLC | griseofulvin oral suspension | 80432-056 |
| >Company | >Ingredient | >NDC |
griseofulvin oral suspension drug variants not containing MENTHOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: METHYLPARABEN
griseofulvin oral suspension drug variants containing METHYLPARABEN
| Company | Ingredient | NDC |
|---|---|---|
| TriRx Huntsville Pharmaceutical Services LLC | griseofulvin oral suspension | 80432-056 |
| >Company | >Ingredient | >NDC |
griseofulvin oral suspension drug variants not containing METHYLPARABEN
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: ORANGE
griseofulvin oral suspension drug variants containing ORANGE
| Company | Ingredient | NDC |
|---|---|---|
| TriRx Huntsville Pharmaceutical Services LLC | griseofulvin oral suspension | 80432-056 |
| >Company | >Ingredient | >NDC |
griseofulvin oral suspension drug variants not containing ORANGE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: PROPYLENE GLYCOL
griseofulvin oral suspension drug variants containing PROPYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| TriRx Huntsville Pharmaceutical Services LLC | griseofulvin oral suspension | 80432-056 |
| >Company | >Ingredient | >NDC |
griseofulvin oral suspension drug variants not containing PROPYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: PROPYLPARABEN
griseofulvin oral suspension drug variants containing PROPYLPARABEN
| Company | Ingredient | NDC |
|---|---|---|
| TriRx Huntsville Pharmaceutical Services LLC | griseofulvin oral suspension | 80432-056 |
| >Company | >Ingredient | >NDC |
griseofulvin oral suspension drug variants not containing PROPYLPARABEN
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SACCHARIN SODIUM
griseofulvin oral suspension drug variants containing SACCHARIN SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| TriRx Huntsville Pharmaceutical Services LLC | griseofulvin oral suspension | 80432-056 |
| >Company | >Ingredient | >NDC |
griseofulvin oral suspension drug variants not containing SACCHARIN SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SODIUM ALGINATE
griseofulvin oral suspension drug variants containing SODIUM ALGINATE
| Company | Ingredient | NDC |
|---|---|---|
| TriRx Huntsville Pharmaceutical Services LLC | griseofulvin oral suspension | 80432-056 |
| >Company | >Ingredient | >NDC |
griseofulvin oral suspension drug variants not containing SODIUM ALGINATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SUCROSE
griseofulvin oral suspension drug variants containing SUCROSE
| Company | Ingredient | NDC |
|---|---|---|
| TriRx Huntsville Pharmaceutical Services LLC | griseofulvin oral suspension | 80432-056 |
| >Company | >Ingredient | >NDC |
griseofulvin oral suspension drug variants not containing SUCROSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: WATER
griseofulvin oral suspension drug variants containing WATER
| Company | Ingredient | NDC |
|---|---|---|
| TriRx Huntsville Pharmaceutical Services LLC | griseofulvin oral suspension | 80432-056 |
| >Company | >Ingredient | >NDC |
griseofulvin oral suspension drug variants not containing WATER
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch